每周一次重组组织型纤溶酶原激活剂封管液的有效性与成本
本研究在加拿大三个中心采用前瞻性前后对照设计,评估每周一次重组组织型纤溶酶原激活剂(rt-PA)封管液与每周三次柠檬酸盐或肝素相比,在高并发症风险血液透析患者中的有效性和成本。结果显示,rt-PA封管显著降低了因导管功能障碍而治疗性使用rt-PA的率(调整后发生率比0.39,95%CI 0.30-0.52),但菌血症率和导管剥离或移除/更换率无差异,且每例入组患者平均总医疗成本增加962加元,主要与rt-PA封管液成本相关。
要点
- 每周一次rt-PA封管可降低导管功能障碍的治疗性rt-PA使用率。
- 该策略未降低菌血症或导管剥离/移除/更换率。
- 每例入组患者平均总医疗成本增加962加元,主要归因于rt-PA成本。
核心结论
- 每周一次rt-PA封管液与治疗性rt-PA使用率降低相关,但未减少菌血症或导管剥离/移除,且增加成本。
研究设计与样本
- 前瞻性前后对照研究,在加拿大三个中心进行,纳入374例患者(平均年龄68岁,52%男性),共506次入组。
- 采用多水平混合效应回归模型进行前后比较,考虑中心聚类和患者可能多次入组。
主要发现
- 治疗性rt-PA使用率的调整后发生率比为0.39(95%CI 0.30-0.52),后干预期显著低于前干预期。
- 菌血症率、导管剥离或移除/更换率无差异。
- 后干预期每例入组患者平均总医疗成本增加962加元,主要与rt-PA封管液成本相关。
临床怎么用
- 对于高并发症风险的血液透析导管患者,可考虑每周一次rt-PA封管以降低治疗性rt-PA使用,但需权衡成本增加。
- 该策略未显示减少菌血症或导管相关手术,临床决策应结合患者个体情况和资源。
局限性
- 研究设计为前后对照,非随机,可能存在时间趋势等混杂因素。
- 患者可能多次入组,统计模型虽已考虑但可能影响独立性。
- 成本分析仅基于加拿大三个中心,外部推广需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Evidence to guide hemodialysis catheter locking solutions is limited. We aimed to assess effectiveness and cost of recombinant tissue plasminogen activator (rt-PA) once per week as a locking solution, compared with thrice weekly citrate or heparin, in patients at high risk of complications. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used a prospective design and pre-post comparison in three sites across Canada. Pre-post comparisons were conducted using multilevel mixed effects regression models accounting for cluster with site and potential enrollment of patients more than once. In the pre period, catheter malfunction was managed as per site-specific standard of care. The intervention in the post period was once weekly rt-PA as a locking solution (with citrate or heparin used for other sessions). The primary outcome was rate of rt-PA use for treatment of catheter malfunction. Secondary outcomes included rates of bacteremia, management of catheter malfunction, and cost. RESULTS: There were 374 patients (mean age 68 years; 52% men) corresponding to 506 enrollments. Mean length of enrollment was 200 days (SD 119) in the pre period and 187 days (SD 101) in the post period. There was a significant decline in rate of rt-PA use for treatment of catheter malfunction in the post compared with pre period (adjusted incidence rate ratio, 0.39; 95% confidence interval, 0.30 to 0.52); however, there was no difference in the rate of bacteremia, or catheter stripping or removal/replacement. The increase in mean total health care cost in the post period was CAD$962 per enrollment, largely related to costs of rt-PA as a locking solution. CONCLUSIONS: Once weekly rt-PA as a catheter locking solution was associated with a reduction in rt-PA use for treatment of catheter malfunction. Our results showing a reduction in rescue rt-PA use are consistent with a prior randomized trial, although we did not observe a reduction in bacteremia or catheter stripping/removal and did observe an increased incremental cost of this strategy primarily accounted for by the cost of the rt-PA.
引用
- Hemmelgarn BR, Manns BJ, Soroka SD, et al. Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution. Clin J Am Soc Nephrol. 2018. PMID: 29335321. doi:10.2215/CJN.08510817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。